RxDoctor Payments Data

Matthew Schuette, MD

Pulmonary Disease · Slidell, LANPI 1679526438

Payments from drug & device makers

$6,842in general payments, 2019–2025

Across 404 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$500
  • Boehringer Ingelheim$481
  • AbbVie$476
  • AstraZeneca$449
  • Sanofi$438
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,77399%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,842 in reported general payments places this provider in the 55th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$105,011
Medicare patients
358
Services billed
1,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter493$395,669
OfevNintedanib Esylate23$216,876
GlassiaAlpha-1-Proteinase Inhibitor12$164,063
Prolastin CAlpha-1-Proteinase Inhibitor13$113,985
Dupixent PenDupilumab21$82,042
Breo ElliptaFluticasone/Vilanterol157$75,595
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$47,727
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$26,517
SymbicortBudesonide/Formoterol Fumarate82$24,044
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$13,166
Albuterol Sulfate HfaAlbuterol Sulfate445$13,053
EliquisApixaban19$12,927
Combivent RespimatIpratropium/Albuterol Sulfate26$12,156
Pirfenidone14$9,381
Spiriva HandihalerTiotropium Bromide11$9,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$2,205$497,781703 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$481$251,30790 claims
Grifols USA, LLCProlastin C$290$113,98513 claims
AstraZenecaBreztri Aerosphere, Symbicort$449$71,771137 claims
MerckDulera$296$4,11612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →